MRIGlobal Announces Chief Innovation Officer
Amy B. Manning-Boğ, Ph.D., Joins from Atreca, Inc. to Lead in New Role
Kansas City, Mo.: (Nov. 1, 2022) – MRIGlobal has announced that Amy B. Manning-Boğ (pronounced: Boh), Ph.D., has joined the institute as its first Chief Innovation Officer. She was formerly Vice President, Drug Discovery & Translational Development for Atreca, Inc. in South San Francisco, Calif. In this newly created role, Manning-Boğ will be responsible for leading the identification and translation of MRIGlobal proprietary intellectual property into commercialization opportunities through licensing, royalties, and new business venture start-ups. She will also lead MRIGlobal’s engagement with the local biotech community.
“Having worked in Silicon Valley and at research non-profits for decades, Amy is a respected scientist and sought-after leader in understanding the challenges and opportunities in scientific research and development. At MRIGlobal, she will foster a culture of innovation that further enables and empowers our researchers to develop unique methods for solving our customers’ most important problems,” said Dr. Ian M. Colrain, President & CEO, MRIGlobal. “Amy also brings a keen appreciation for Midwestern culture, coupled with first-hand knowledge of Kansas City’s academic and scientific ecosystem. Her experience will help us capitalize on our intellectual property, providing an additional revenue stream from licensing that will support our staff, future research, and investments in the institute.”
Manning-Boğ has built her career on being a scientific leader and executive in discovery research and translation with a history of achievement in strategic planning, operations, and financial goals in small and mid-sized companies. She has led from concept to development many innovative, novel therapeutics including biologics, small molecules, and gene-modifying agents across multiple domains including neuroscience, oncology, and metabolic diseases. She has a strong track record of leading and contributing effectively in multidisciplinary and team-based environments that are fast-paced, collaborative, and scientifically rigorous.
“MRIGlobal is at the epicenter of breakthroughs in areas like infectious disease diagnostics, vaccine and therapeutic development and testing, and pharmaceutical development. I couldn’t be more thrilled to join the team and implement an ongoing system of innovation that creates even greater value for our customers, end-users, and the institute,” said Manning- Boğ. “I was drawn to MRIGlobal because there is such outstanding scientific talent and world-class research taking place, and I think the opportunities to grow intellectual property are unmatched. Too, I grew up near Joplin and attended school in Springfield and Kansas City, so this is an exciting homecoming for me.”
Manning-Boğ earned her B.S. in Biology at Missouri State University in Springfield, and an Interdisciplinary Ph.D. in Molecular/Cell Biology and Biochemistry at University of Missouri-Kansas City.
MRIGlobal improves the health and safety of people everywhere by addressing some of the world’s greatest threats and complex biological, chemical, and engineering challenges. Founded in 1944 as an independent, not-for-profit organization, MRIGlobal provides customized research and development services to health and defense-focused organizations in need of innovative and multidisciplinary solutions. This includes expertise in clinical research support, infectious disease and biological threat agent detection, global biological engagement, in vitro diagnostics, and laboratory management and operations. To learn more, visit mriglobal.org.